Atai Beckley N.V.
ataibeckley.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q3 FY2025 10-Q, filed Nov 12, 2025. Its latest SEC filing is a 144 from Mar 20, 2026.
10-Q for Q3 FY2025, filed Nov 12, 2025
The sections below describe the company as of the FY2024 annual report.
What Did They Do?
Develops investigational mental health treatments, including psychedelic medicines for depression and anxiety, for patients with mental health disorders.
10-K for FY2024, filed Mar 17, 2025We are a clinical-stage biopharmaceutical company on a mission to develop highly effective mental health treatments to transform patient…View ↗
Our research is focused on developing rapid-acting, robust, and durable mental health treatments that can deliver large-scale patient…View ↗
We have built a diversified pipeline of psychedelic product candidates that target mental health disorders that we believe have significant…View ↗
VLS-01: DMT for TRDView ↗
Who Were Their Customers?
The company works with counterparties in research, development, manufacturing and commercialization collaborations, including parties that license its intellectual property or use its manufacturing services.
10-K for FY2024, filed Mar 17, 2025The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is…View ↗
The Company may enter into collaboration and out-licensing arrangements for research and development, manufacturing, and commercialization…View ↗
The arrangements may contain multiple components, which may include (i) licenses, or options to obtain licenses to the Company’s…View ↗
How Were They Changing?
- Net income
-
Sources
10-Q for Q3 FY2025, filed Nov 12, 2025
−$61.1MView ↗
- ▲ +132% (Loss)
- vs −$26.3M in Q3 FY2024
-
Nov 5, 2025
Completed acquisition of Beckley Psytech and changed the company name.
The company acquired the remaining shares of Beckley Psytech in an all-share transaction and changed its name to Atai Beckley N.V.
Sources
8-K, filed Nov 5, 2025
On November 5, 2025, Atai Beckley N.V. (f/k/a ATAI Life Sciences N.V.) (“atai” or the “Company”) completed its previously announced…View ↗
-
Oct 16, 2025
FDA granted Breakthrough Therapy designation to BPL-003.
The designation is for BPL-003 as a treatment for adults with treatment-resistant depression.
Sources
8-K, filed Oct 16, 2025
On October 16, 2025, the Company and Beckley Psytech announced that the U.S. Food and Drug Administration (the “FDA”) granted Breakthrough…View ↗
Added digital therapeutics
The older report describes digital therapeutics as part of its therapeutic focus and lists ongoing digital support as a business pillar. The latest report instead describes an in-house pipeline of drug candidates and strategic investments in companies developing drug candidates.
10-K for FY2021, filed Mar 30, 2022 10-K for FY2024, filed Mar 17, 2025Our business is organized along three strategic pillars:View ↗
Ongoing digital support: additional care that is provided to patients before, during, and after initial treatment interventions; andView ↗
Therapeutic focus in mental health. We are focused on developing innovative therapeutics for mental health disorders based on new insights…View ↗
Who Did They Compete With?
Competes with Johnson & Johnson, Axsome Therapeutics, GH Research, Cybin, Neumora Therapeutics, Alto Neuroscience, Neurocrine Biosciences, COMPASS, Newron Pharmaceuticals, AbbVie, VistaGen Therapeutics, Engrail Therapeutics, Neuphoria Therapeutics, MindMed, Intracellular-Therapies, and Lykos Therapeutics
10-K for FY2024, filed Mar 17, 2025Multiple therapies for depression exist, including common pharmacological treatments such as anti-depressants and psychosocial…View ↗
Loading...
